guest ::
| Home > Publications database > KRAS inhibitors: resistance drivers and combinatorial strategies. > print |
| Home > Publications database > KRAS inhibitors: resistance drivers and combinatorial strategies. > print |
| 001 | 296069 | ||
| 005 | 20250214112551.0 | ||
| 024 | 7 | _ | |a 10.1016/j.trecan.2024.11.009 |2 doi |
| 024 | 7 | _ | |a pmid:39732595 |2 pmid |
| 024 | 7 | _ | |a 2405-8033 |2 ISSN |
| 024 | 7 | _ | |a 2405-8025 |2 ISSN |
| 024 | 7 | _ | |a altmetric:172509914 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2025-00017 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Isermann, Tamara |0 P:(DE-He78)4fa7e3d6860d7d25296138a72c3ef7bc |b 0 |u dkfz |
| 245 | _ | _ | |a KRAS inhibitors: resistance drivers and combinatorial strategies. |
| 260 | _ | _ | |a Amsterdam |c 2025 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1739528676_2240 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2025 Feb;11(2):91-116 |
| 520 | _ | _ | |a In 1982, the RAS genes HRAS and KRAS were discovered as the first human cancer genes, with KRAS later identified as one of the most frequently mutated oncogenes. Yet, it took nearly 40 years to develop clinically effective inhibitors for RAS-mutant cancers. The discovery in 2013 by Shokat and colleagues of a druggable pocket in KRAS paved the way to FDA approval of the first covalently binding KRASG12C inhibitors, sotorasib and adagrasib, in 2021 and 2022, respectively. However, rather than marking the end of a successful assault on the Mount Everest of cancer research, this landmark only revealed new challenges in RAS drug discovery. In this review, we highlight the progress on defining resistance mechanisms and developing combination treatment strategies to improve patient responses to KRAS therapies. |
| 536 | _ | _ | |a 899 - ohne Topic (POF4-899) |0 G:(DE-HGF)POF4-899 |c POF4-899 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a KRAS |2 Other |
| 650 | _ | 7 | |a colorectal carcinoma |2 Other |
| 650 | _ | 7 | |a drug resistance |2 Other |
| 650 | _ | 7 | |a non-small cell lung cancer |2 Other |
| 650 | _ | 7 | |a pancreatic ductal adenocarcinoma |2 Other |
| 700 | 1 | _ | |a Sers, Christine |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Der, Channing J |b 2 |
| 700 | 1 | _ | |a Papke, Bjoern |0 P:(DE-HGF)0 |b 3 |
| 773 | _ | _ | |a 10.1016/j.trecan.2024.11.009 |g p. S2405803324002759 |0 PERI:(DE-600)2852626-0 |n 2 |p 91-116 |t Trends in cancer |v 11 |y 2025 |x 2405-8033 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:296069 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)4fa7e3d6860d7d25296138a72c3ef7bc |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-HGF)0 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b TRENDS CANCER : 2022 |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-25 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-08-25 |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b TRENDS CANCER : 2022 |d 2023-08-25 |
| 920 | 1 | _ | |0 I:(DE-He78)BE01-20160331 |k BE01 |l DKTK Koordinierungsstelle Berlin |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)BE01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|